Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis

Clinical Rheumatology

Volumn 27, Issue 7, 2008, Pages 927-932

  Laas, Karin ^a,b   Peltomaa, Ritva ^a   Kautiainen, Hannu ^c   Leirisalo Repo, Marjatta ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b East Tallinn Central Hospital   (Estonia)

^c RHEUMATISM FOUNDATION HOSPITAL   (Finland)

Author keywords

Anti tumour necrosis factor; Etanercept; Infliximab; Rheumatoid arthritis; Switch treatment

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PREDNISOLONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMYELINATING NEUROPATHY; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DISEASE CONTROL; DRUG CHOICE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; INFECTION; LUPUS LIKE SYNDROME; MALE; MONOTHERAPY; NEPHROTOXICITY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUSTULOSIS PALMOPLANTARIS; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SIDE EFFECT; SKIN ALLERGY; SURVIVAL TIME; TUBERCULOSIS; UNIVERSITY HOSPITAL; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 45049086041     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-008-0880-6     Document Type: Article

References (22)

1. Lipsky PE, van der Heijde DM, St Clair EW et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343:1594-1602
2. Moreland LW, Baumgartner SW, Schiff MH et al (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337:141-147
3. Van den Brande JM, Braat H, van den Brink GR et al (2003) Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124:1774-1785
4. Nikas SN, Voulgari PV, Alamanos Y et al (2006) Efficacy and safety of switching from infliximab to adalimumab: A comparative controlled study. Ann Rheum Dis 65:257-260
5. Haraoui B, Keystone EC, Thorne JC et al (2004) Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. J Rheumatol 31:2356-2359
6. Sanmarti R, Gomez-Puerta JA, Rodriguez-Cros JR et al (2004) Etanercept in rheumatoid arthritis patients with a poor therapeutic response to infliximab. Med Clin (Barc) 122:321-324
7. Hansen KE, Hildebrand JP, Genovese MC et al (2004) The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol 31:1098-1102
8. Ang HT, Helfgott S (2003) Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis? J Rheumatol 30:2315-2318
9. van Vollenhoven R, Harju A, Brannemark S et al (2003) Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann Rheum Dis 62:1195-1198
10. Wick MC, Ernestam S, Lindblad S et al (2005) Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): Results from the STURE registry at Karolinska University Hospital. Scand J Rheumatol 34:353-358
11. Cohen G, Courvoisier N, Cohen JD et al (2005) The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. Clin Exp Rheumatol 23:795-800
12. Buch MH, Bingham SJ, Bejarano V et al (2007) Therapy of patients with rheumatoid arthritis: Outcome of infliximab failures switched to etanercept. Arthritis Rheum 57:448-453
13. Hjardem E, Ostergaard M, Podenphant J et al (2007) Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor? Ann Rheum Dis 66:1184-1189
14. Hakala M, Nieminen P, Manelius J (1994) Joint impairment is strongly correlated with disability measured by self-report questionnaires. Functional status assessment of individuals with rheumatoid arthritis in a population based series. J Rheumatol 21:64-69
15. Prevoo ML, van't Hof MA, Kuper HH et al (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44-48
16. Pinals RS, Masi AT, Larsen RA (1981) Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 24:1308-1315
17. Efron B, Tibshirani RJ (1994) An introduction to the bootstrap. Chapman and Hall, London
18. Fransen J, Creemers MC, Van Riel PL (2004) Remission in rheumatoid arthritis: Agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 43:1252-1255
19. Walsh CA, Minnock P, Slattery C et al (2007) Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis. Rheumatology (Oxford) 46:1148-1152
20. Nuijten MJ, Engelfriet P, Duijn K et al (2001) A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis. Pharmacoeconomics 19:1051-1064
21. Gomez-Reino JJ, Carmona L, BIOBASADER Group (2006) Switching TNF antagonists in patients with chronic arthritis: An observational study of 488 patients over a four-year period. Arthritis Res Ther 8:R29
22. Hyrich KL, Lunt M, Watson KD et al (2007) Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 56:13-20